Chihiro Matsumoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Chihiro Matsumoto has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Hideo Baba
Institute of Pathology, University Hospital Essen, University Duisburg-Essen, Germany (D.M., H.A.B.).
4 shared publications - Masaaki Iwatsuki
Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
4 shared publications - Kohei Yamashita
Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
2 shared publications - Kojiro Eto
Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
2 shared publications - Koshi Mimori
Department of Surgery Kyushu University Beppu Hospital Oita Japan
2 shared publications - Naoya Yoshida
Department of Gastroenterological Surgery, Graduate School of Medical Sciences Kumamoto University Kumamoto Japan
2 shared publications
Latest Publications
- 14 February 2026
- Published by Wiley in Hepatology Research
- Vol. 56 (5) , 806-819
Identification of the Inflammatory Cytokine Tumor Necrosis Factor Superfamily 4 as an Oncogenic Driver and Potential Druggable Target in Hepatocellular Carcinoma
Aim: In hepatocellular carcinoma (HCC), molecularly targeted therapies have been the major focus of recent research. In this study, we evaluated the clinical and biological roles of tumor necrosis factor superfamily 4 (TNFSF4), an inflammatory cytokine, as a therapeutic target in HCC. Methods: Using a bioinformatics approach, we identified TNFSF4 as a candidate driver in HCC and assessed the prognostic significance of TNFSF4. Its biological role in HCC was clarified through in vitro experiments, such as cell cycle/colony formation assays, using TNFSF4 ‐overexpressing HCC cells. Moreover, a candidate repositioned drug was identified from public drug sensitivity data, and its antitumor effects and mechanisms were examined both in vitro and in vivo. Results: Analysis of The Cancer Genome Atlas datasets for HCC revealed that TNFSF4 was overexpressed in HCC cells owing to increased DNA copy numbers. Additionally, high TNFSF4 expression was significantly associated with poorer prognosis. Immunohistochemical staining showed that TNFSF4 was overexpressed in the cytoplasm of tumor cells. In vitro analysis showed that TNFSF4 overexpression promoted the G 1 /S transition in the cell cycle, stimulated proliferation, and increased phosphoinositol‐3‐kinase (PI3K) phosphorylation, resulting in p21 downregulation and enhanced Rb phosphorylation. In bioinformatics‐based drug repositioning analysis, fluspirilene, a typical antipsychotic agent, was identified as a repositioned drug that inhibited HCC growth through cyclin D1 suppression, downstream of TNFSF4. Conclusions: TNFSF4 was a candidate driver and a prognostic biomarker, promoting HCC progression by activating the PI3K/Akt signaling pathway. Furthermore, fluspirilene may have applications as a repositioned drug for HCC with high TNFSF4 expression.
- 14 February 2026
- Published by Wiley in Hepatology Research
- Vol. 56 (5) , 806-819
Identification of the Inflammatory Cytokine Tumor Necrosis Factor Superfamily 4 as an Oncogenic Driver and Potential Druggable Target in Hepatocellular Carcinoma
Aim: In hepatocellular carcinoma (HCC), molecularly targeted therapies have been the major focus of recent research. In this study, we evaluated the clinical and biological roles of tumor necrosis factor superfamily 4 (TNFSF4), an inflammatory cytokine, as a therapeutic target in HCC. Methods: Using a bioinformatics approach, we identified TNFSF4 as a candidate driver in HCC and assessed the prognostic significance of TNFSF4. Its biological role in HCC was clarified through in vitro experiments, such as cell cycle/colony formation assays, using TNFSF4 ‐overexpressing HCC cells. Moreover, a candidate repositioned drug was identified from public drug sensitivity data, and its antitumor effects and mechanisms were examined both in vitro and in vivo. Results: Analysis of The Cancer Genome Atlas datasets for HCC revealed that TNFSF4 was overexpressed in HCC cells owing to increased DNA copy numbers. Additionally, high TNFSF4 expression was significantly associated with poorer prognosis. Immunohistochemical staining showed that TNFSF4 was overexpressed in the cytoplasm of tumor cells. In vitro analysis showed that TNFSF4 overexpression promoted the G 1 /S transition in the cell cycle, stimulated proliferation, and increased phosphoinositol‐3‐kinase (PI3K) phosphorylation, resulting in p21 downregulation and enhanced Rb phosphorylation. In bioinformatics‐based drug repositioning analysis, fluspirilene, a typical antipsychotic agent, was identified as a repositioned drug that inhibited HCC growth through cyclin D1 suppression, downstream of TNFSF4. Conclusions: TNFSF4 was a candidate driver and a prognostic biomarker, promoting HCC progression by activating the PI3K/Akt signaling pathway. Furthermore, fluspirilene may have applications as a repositioned drug for HCC with high TNFSF4 expression.
- Open Access
- 31 October 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (44)
Genomic and transcriptomic landscape of carcinogenesis in patients with gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS)
Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) is an autosomal dominant syndrome characterized by polyposis localized in the gastric body and fundus with a strong tendency for adenocarcinoma. The genetic mutations that accumulate during the progression from normal mucosa through polyp to carcinoma in GAPPS remain unclear. We investigated the evolutionary process from normal mucosa to polyp and carcinoma in GAPPS. Through comprehensive mutational and transcriptome analyses, we aimed to provide insights into the biology of this disease. Whole-exome sequencing and RNA sequencing were performed on carcinoma, polyp, and normal mucosa samples from multiple sites from seven patients with GAPPS (n = 54 samples). We comprehensively investigated genomic alterations (including copy number alterations and somatic mutations), clonal architecture, and transcriptome dynamics during carcinogenesis. Genomic evolutionary analysis showed that in GAPPS, somatic mutations of APC occur in carcinoma and polyp while mutations of KRAS additionally occur in carcinoma. We also found the co-occurrence of APC and KRAS mutations in carcinoma recurrently both across cases and within subclones of the same case. The co-occurrence of APC/KRAS mutations may contribute to the carcinogenesis of GAPPS. Our study provides detailed information on the genomic and transcriptomic landscape in GAPPS carcinogenesis, conferring valuable insights into its underlying mechanisms.
- 31 October 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (44)
Open AccessGenomic and transcriptomic landscape of carcinogenesis in patients with gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS)
Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) is an autosomal dominant syndrome characterized by polyposis localized in the gastric body and fundus with a strong tendency for adenocarcinoma. The genetic mutations that accumulate during the progression from normal mucosa through polyp to carcinoma in GAPPS remain unclear. We investigated the evolutionary process from normal mucosa to polyp and carcinoma in GAPPS. Through comprehensive mutational and transcriptome analyses, we aimed to provide insights into the biology of this disease. Whole-exome sequencing and RNA sequencing were performed on carcinoma, polyp, and normal mucosa samples from multiple sites from seven patients with GAPPS (n = 54 samples). We comprehensively investigated genomic alterations (including copy number alterations and somatic mutations), clonal architecture, and transcriptome dynamics during carcinogenesis. Genomic evolutionary analysis showed that in GAPPS, somatic mutations of APC occur in carcinoma and polyp while mutations of KRAS additionally occur in carcinoma. We also found the co-occurrence of APC and KRAS mutations in carcinoma recurrently both across cases and within subclones of the same case. The co-occurrence of APC/KRAS mutations may contribute to the carcinogenesis of GAPPS. Our study provides detailed information on the genomic and transcriptomic landscape in GAPPS carcinogenesis, conferring valuable insights into its underlying mechanisms.
- Open Access
- 26 March 2024
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 8 (5) , 787-794
Textbook outcome contributes to long‐term prognosis in elderly patients with esophageal squamous cell carcinoma
Purpose: Textbook outcome (TO) is a composite quality measurement of outcomes for evaluating surgical procedures. We investigated whether TO can be used to predict outcomes after curative resection for esophageal squamous cell carcinoma (ESCC) in elderly patients.Methods: We retrospectively analyzed 105 patients who underwent curative esophagectomy for ESCC from 2005 to 2020. In accordance with previous reports, TO consisted of 10 parameters. The patients were divided into two groups: those who achieved TO (TO) and those who failed to achieve TO (non‐TO). We evaluated the association between TO and long‐term survival.Results: TO was achieved in 28 (26%) patients. The patients in the TO group were significantly older (p = 0.02). The parameter with the lowest achievement rate was “No hospital stay ≥21 days”. The patients in non‐TO group had significantly shorter overall survival than those in TO group (p = 0.03). Multivariable Cox regression analyses of overall survival revealed that lymph node metastasis (hazard ratio [HR], 3.42; 95% confidence interval [CI], 1.73–6.78; p < 0.0002) and non‐TO (HR, 2.37; 95% CI, 1.05–5.65; p = 0.03) were significantly associated with poor overall survival.Conclusion: TO can be used to predict outcomes after curative esophagectomy in elderly patients with ESCC.
- 26 March 2024
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 8 (5) , 787-794
Open AccessTextbook outcome contributes to long‐term prognosis in elderly patients with esophageal squamous cell carcinoma
Purpose: Textbook outcome (TO) is a composite quality measurement of outcomes for evaluating surgical procedures. We investigated whether TO can be used to predict outcomes after curative resection for esophageal squamous cell carcinoma (ESCC) in elderly patients.Methods: We retrospectively analyzed 105 patients who underwent curative esophagectomy for ESCC from 2005 to 2020. In accordance with previous reports, TO consisted of 10 parameters. The patients were divided into two groups: those who achieved TO (TO) and those who failed to achieve TO (non‐TO). We evaluated the association between TO and long‐term survival.Results: TO was achieved in 28 (26%) patients. The patients in the TO group were significantly older (p = 0.02). The parameter with the lowest achievement rate was “No hospital stay ≥21 days”. The patients in non‐TO group had significantly shorter overall survival than those in TO group (p = 0.03). Multivariable Cox regression analyses of overall survival revealed that lymph node metastasis (hazard ratio [HR], 3.42; 95% confidence interval [CI], 1.73–6.78; p < 0.0002) and non‐TO (HR, 2.37; 95% CI, 1.05–5.65; p = 0.03) were significantly associated with poor overall survival.Conclusion: TO can be used to predict outcomes after curative esophagectomy in elderly patients with ESCC.
- Open Access
- 26 March 2024
- Published by Akademiai Kiado Zrt. in Journal of Behavioral Addictions
- Vol. 13 (1) , 276-292
Mental health professionals' use of the ICD-11 classification of impulse control disorders and behavioral addictions: An international field study
Background and aims: The ICD-11 chapter on mental, behavioral and neurodevelopmental disorders contains new controversial diagnoses including compulsive sexual behavior disorder (CSBD), intermittent explosive disorder (IED) and gaming disorder. Using a vignette-based methodology, this field study examined the ability of mental health professionals (MHPs) to apply the new ICD-11 diagnostic requirements for impulse control disorders, which include CSBD and IED, and disorders due to addictive behaviors, which include gaming disorder, compared to the previous ICD-10 guidelines.Methods: Across eleven comparisons, members of the WHO's Global Clinical Practice Network (N = 1,090) evaluated standardized case descriptions that were designed to test key differences between the diagnostic guidelines of ICD-11 and ICD-10.Results: The ICD-11 outperformed the ICD-10 in the accuracy of diagnosing impulse control disorders and behavioral addictions in most comparisons, while the ICD-10 was not superior in any. The superiority of the ICD-11 was particularly clear where new diagnoses had been added to the classification system or major revisions had been made. However, the ICD-11 outperformed the ICD-10 only in a minority of comparisons in which mental health professionals were asked to evaluate cases with non-pathological high involvement in rewarding behaviors.Discussion and Conclusions: Overall, the present study indicates that the ICD-11 diagnostic requirements represent an improvement over the ICD-10 guidelines. However, additional efforts, such as training programs for MHPs and possible refinements of diagnostic guidance, are needed to avoid over-diagnosis of people who are highly engaged in a repetitive and rewarding behavior but below the threshold for a disorder.
- 26 March 2024
- Published by Akademiai Kiado Zrt. in Journal of Behavioral Addictions
- Vol. 13 (1) , 276-292
Open AccessMental health professionals' use of the ICD-11 classification of impulse control disorders and behavioral addictions: An international field study
Background and aims: The ICD-11 chapter on mental, behavioral and neurodevelopmental disorders contains new controversial diagnoses including compulsive sexual behavior disorder (CSBD), intermittent explosive disorder (IED) and gaming disorder. Using a vignette-based methodology, this field study examined the ability of mental health professionals (MHPs) to apply the new ICD-11 diagnostic requirements for impulse control disorders, which include CSBD and IED, and disorders due to addictive behaviors, which include gaming disorder, compared to the previous ICD-10 guidelines.Methods: Across eleven comparisons, members of the WHO's Global Clinical Practice Network (N = 1,090) evaluated standardized case descriptions that were designed to test key differences between the diagnostic guidelines of ICD-11 and ICD-10.Results: The ICD-11 outperformed the ICD-10 in the accuracy of diagnosing impulse control disorders and behavioral addictions in most comparisons, while the ICD-10 was not superior in any. The superiority of the ICD-11 was particularly clear where new diagnoses had been added to the classification system or major revisions had been made. However, the ICD-11 outperformed the ICD-10 only in a minority of comparisons in which mental health professionals were asked to evaluate cases with non-pathological high involvement in rewarding behaviors.Discussion and Conclusions: Overall, the present study indicates that the ICD-11 diagnostic requirements represent an improvement over the ICD-10 guidelines. However, additional efforts, such as training programs for MHPs and possible refinements of diagnostic guidance, are needed to avoid over-diagnosis of people who are highly engaged in a repetitive and rewarding behavior but below the threshold for a disorder.
- Open Access
- 21 June 2023
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 7 (5) , 725-732
The comprehensive review of gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) from diagnosis and treatment
Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) was first proposed by Wothley et al. in 2012 as a rare familial gastric cancer syndrome associated with an autosomal dominant form of inheritance. GAPPS is characterized by gastric basal gland polyposis from the hilum to the body of the stomach. Li et al. in 2016 showed that the cause of the disease is a point mutation in the promotor 1B region of the APC gene, and genetic testing was used to confirm the diagnosis. If the patient has already developed gastric cancer, treatment should be based on the usual treatment for gastric cancer. If no distant metastases exist, a good prognosis can be expected by performing a total gastrectomy. On the other hand, patients with distant metastasis have a poor prognosis. In the case of dysplasia, prophylactic total gastrectomy is recommended, but because it is highly invasive and postoperative postgastrectomy syndrome must be considered, the decision should be made with careful consideration of the patient's background. Therefore, there are no guidelines for screening for GAPPS, the timing of prophylactic total gastrectomy, or methods of endoscopic surveillance. Because GAPPS is a rare disease, its natural history is still unclear. Further case series are needed to elucidate the molecular biology and clinicopathological features of GAPPS and to establish clinical management, including diagnosis, treatment, and surveillance. In this review, we provide an overview of GAPPS, its clinical management, and its problems, which will be useful for the treatment of GAPPS.
- 21 June 2023
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 7 (5) , 725-732
Open AccessThe comprehensive review of gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) from diagnosis and treatment
Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) was first proposed by Wothley et al. in 2012 as a rare familial gastric cancer syndrome associated with an autosomal dominant form of inheritance. GAPPS is characterized by gastric basal gland polyposis from the hilum to the body of the stomach. Li et al. in 2016 showed that the cause of the disease is a point mutation in the promotor 1B region of the APC gene, and genetic testing was used to confirm the diagnosis. If the patient has already developed gastric cancer, treatment should be based on the usual treatment for gastric cancer. If no distant metastases exist, a good prognosis can be expected by performing a total gastrectomy. On the other hand, patients with distant metastasis have a poor prognosis. In the case of dysplasia, prophylactic total gastrectomy is recommended, but because it is highly invasive and postoperative postgastrectomy syndrome must be considered, the decision should be made with careful consideration of the patient's background. Therefore, there are no guidelines for screening for GAPPS, the timing of prophylactic total gastrectomy, or methods of endoscopic surveillance. Because GAPPS is a rare disease, its natural history is still unclear. Further case series are needed to elucidate the molecular biology and clinicopathological features of GAPPS and to establish clinical management, including diagnosis, treatment, and surveillance. In this review, we provide an overview of GAPPS, its clinical management, and its problems, which will be useful for the treatment of GAPPS.
- 20 November 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (2) , 1253-1254
ASO Visual Abstract: Dynamic Alteration in HLA-E Expression and Soluble HLA-E via Interaction with Natural Killer Cells in Gastric Cancer
- 20 November 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (2) , 1253-1254
ASO Visual Abstract: Dynamic Alteration in HLA-E Expression and Soluble HLA-E via Interaction with Natural Killer Cells in Gastric Cancer
- 1 July 2001
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 15 (4) , 354-356
Vesicular prurigo pigmentosa cured by minocycline
We present a case of prurigo pigmentosa associated with vesicles that we call ‘vesicular prurigo pigmentosa’. The subject was treated using minocycline with good results and no recurrence of the lesions over a 2‐year period.
- 1 July 2001
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 15 (4) , 354-356
Vesicular prurigo pigmentosa cured by minocycline
We present a case of prurigo pigmentosa associated with vesicles that we call ‘vesicular prurigo pigmentosa’. The subject was treated using minocycline with good results and no recurrence of the lesions over a 2‐year period.